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In order to identify RCTs medical databases were searched:
e.g. Medline, EmBase and Cochrane Library. Calculations and
metaanalyses were performed using StatsDirect statistical soft-
ware. RESULTS: Nineteen RCTs (treatment period 2–16 weeks),
in which a total number of 1795 patients with PAH participated,
were included in the SR. All patients continued CT with antico-
agulants, vasodilators, diuretics and/or digitalis glycosides
Bosentan, epoprostenol, iloprost and sildenaﬁl signiﬁcantly
increase exercise capacity (according to the NYHA classiﬁca-
tion) comparing to placebo in the PAH population: bosentan
vs. placebo: OR = 2.25 (95%CI: 1.21; 4.18); epoprostenol vs.
placebo: OR = 37.99 (95%CI: 8.43; 171.22); iloprost vs.
placebo: OR = 2.25 (95%CI: 1.02; 5.13), sildenaﬁl vs. placebo:
OR = 6.94 (95%CI: 2.78; 17.31). In bosentan, iloprost, sildenaﬁl
and treprostinil groups signiﬁcantly higher improvement in exer-
cise capacity, measured using the 6-minute walk test, was found
comparing to placebo: WMD = 43.33 m (95%CI: 27.55; 59.12)
for bosentan vs. placebo; 36.4 m (p = 0.004)—iloprost vs.
placebo; 55.82 m (95%CI: 38.03; 73.61)—sildenaﬁl vs. placebo
and 16.00 m (95%CI: 4.40; 27.60)—treprostinil vs. placebo. In
safety analysis no statistically signiﬁcant differences were
observed between bosentan and placebo as well as sildenaﬁl and
placebo groups. Comparing to placebo, in epoprostenol group
signiﬁcantly more often jaw pain, nausea and diarrhea occurred,
in iloprost group there was higher incidence of serious syncope or
ﬂushing and jaw pain and in the treprostinil group—sudden
vasodilation, edema, jaw pain and reaction, pain, hematoma or
induration at the injection site. CONCLUSIONS: The use of
these ﬁve drugs in addition to CT is more effective than CT alone.
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OBJECTIVES: The effectiveness of drug-eluting stents (DES) and
bare-metal stents (BMS) in reducing restenosis and rate of major
adverse cardiac events (MACE) in selected patients has been
demonstrated by the randomized controlled trials. Despite the
better efﬁcacy of DES over BMS in reducing revascularization,
the initial cost of DES is much higher than BMS, which limits its
use in clinical practice. We aimed to evaluate the clinical outcome
of BMS and DES placement in coronary artery disease patients
and estimate the cost of BMS and DES placement in a Chinese
population. METHODS: It was a retrospective cross-sectional
study. We included all patients who underwent PCI with stent
placement of either DES or BMS in a tertiary public hospital in
Hong Kong during January to December 2005. Patients were
followed up for the occurrence of MACE within 12 months of
the index stent placement. MACE was deﬁned as cardiac death,
non-fatal myocardial infarction and target lesion revasculariza-
tion. Direct medical costs were estimated based on the proce-
dural cost, hospitalization, medications, cardiac follow-up and
repeated interventions taken. RESULTS: This analysis included
447 patients. Twelve-month MACE rate was 10.6% in BMS
versus 3.0% in DES (p = 0.001). Rate of cardiac death was
2.9% in BMS versus 0.0% in DES group (p = 0.109). The
mean 12-month cost per patient after index PCI was
USD 9802.9  8503.8 (median = 8721.8) in BMS and USD
10052.1  5624.9 (median = 8786.7) in DES. On average, DES
costs USD 1605.1 more than BMS per patient. CONCLUSIONS:
DES demonstrated a signiﬁcant reduction in 12-month MACE
compared with BMS. Although DES carried a higher procedural
cost, it had similar 12-month costs with BMS due to less post-
PTCA intervention. DES was proved to be cost-effective to be
used in Hong Kong public hospitals.
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OBJECTIVES: To explore the efﬁcacy of irbesartan in reducing
blood pressure (BP) compared to candesartan, in a real-world
setting. METHODS: We analysed the records of 10,338 (5,425
candesartan; 4,913 irbesartan) adult patients with hypertension
who were initiated on the two agents between 1998 and 2006
using the UK THIN GP database. The analyses presented report
the comparisons for General hypertensive patients (systolic BP
(SBP) 140 mmHg, diastolic BP (DBP) 90 mmHg) and Severe
hypertensive patients (SBP  180 mmHg, DBP  110 mmHg)
on either ARB over the ﬁrst 2 years of treatment. RESULTS: In
the General hypertensive group mean SBP reductions at 1 year
reached 14.7 mmHg for irbesartan vs. 13.6 mmHg for cande-
sartan. Mean DBP reductions reached 8.5 mmHg for irbesartan
and 7.1 mmHg for candesartan. In the Severe group, mean SBP
reductions reached 31.6 mmHg for irbesartan vs. 31.2 mmHg
for candesartan. Mean DBP reductions reached 15.8 mmHg for
irbesartan vs. 13.4 mmHg for candesartan. Similar comparisons
were observed in the second year analysis. All but one of the
comparisons were statistically signiﬁcant in a multivariate analy-
sis after adjusting for baseline BP, age, sex, weight, diabetes
status, practice effect, socioeconomic status, 1st line vs. subse-
quent line usage, number of prior comorbidities, hypertensive
diagnosis status and type of and number of co-therapies pre-
scribed. In the General hypertensive population, patients receiv-
ing irbesartan showed a greater mean reduction in SBP of
1.18 mmHg (p < 0.001) and of 0.55 mmHg (p < 0.001) in DBP
over 2 years compared to those receiving candesartan. Similar
differences among therapies were observed in Severe patients,
1.79 mmHg in SBP (p = 0.02), -0.10 mmHg in DBP (p = 0.747).
Signiﬁcance may have been affected by the small number of
patients in the Severe group. CONCLUSIONS: In a real-world
setting, patients receiving irbesartan are observed to achieve
greater BP reductions compared to those receiving candesartan.
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OBJECTIVES: Missing a single dose is the most common error in
patients on once-daily antihypertensives. In this study we
explored whether a drug which maintains its efﬁcacy for >48 hrs
offers adequate blood pressure (BP) reduction in the face of
typical dosing errors. METHODS: Mean BP reduction and rate
of loss of efﬁcacy after stopping the drug were derived from a
randomized study comparing aliskiren, ramipril, and irbesartan
in 654 hypertensives. An independent database of dosing histo-
ries, compiled in patients on once-daily antihypertensives and
recording electronically whether and when doses were taken, was
used to describe the distribution of dosing errors. From this, each
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